Lead Product(s): Galacto-oligosaccharide
Therapeutic Area: Gastroenterology
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger January 21, 2020
The merged company will focus on the development of Qualigen’s nanotechnology therapies for the treatment of cancer and infectious diseases, while also continuing to operate its profitable diagnostic business.